This large, multicentre, randomized trial was conducted with patients at high risk for bleeding who had undergone biodegradable polymer sirolimus-eluting stent implantation to assess whether one month of dual antiplatelet therapy preserves the net and major adverse cardiovascular events. And if so, whether it mitigates major or nonmajor clinically relevant bleeding occurrences, compared with longer treatment durations.

In this episode, Prof Marco Valgimigli, MD, PhD, FESC and Poonam Velagapudi MD, MS discuss ESC Late Breaker: MASTER DAPT: dual antiplatelet therapy after coronary stenting in high bleeding risk patients.

post
Source

https://www.acc.org/latest-in-cardiology/articles/2021/09/27/12/00/accel-lite-2021sept28-esc-2021

Tags

Therapeutic Modality ,Interventional Cardiology,Bare metal stent,Drug Eluting Stent